The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
Open accessPublished version of a preprint
Abstract
Ex vivo systems that incorporate features of the tumor microenvironment and model the dynamic response to immune checkpoint blockade (ICB) may facilitate efforts in precision immuno-oncology and the development of effective combination therapies. Here, we demonstrate the ability to interrogate ex vivo response to ICB using murine- and patient-derived organotypic tumor spheroids (MDOTS/PDOTS). MDOTS/PDOTS isolated from mouse and human tumors retain autologous lymphoid and myeloid cell populations and respond to ICB in short-term three-dimensional microfluidic culture. Response and resistance to ICB was recapitulated using MDOTS derived from established immunocompetent mouse tumor models. MDOTS profiling demonstrated that TBK1/IKKϵ inhibition enhanced response to PD-1 blockade, which effectively predicted tumor response in vivo. Systematic profiling of secreted cytokines in PDOTS captured key features associated with response and resistance to PD-1 blockade. Thus, MDOTS/PDOTS profiling represents a novel platform to evaluate ICB using established murine models as well as clinically relevant patient specimens. Significance: Resistance to PD-1 blockade remains a challenge for many patients, and biomarkers to guide treatment are lacking. Here, we demonstrate feasibility of ex vivo profiling of PD-1 blockade to interrogate the tumor immune microenvironment, develop therapeutic combinations, and facilitate precision immuno-oncology efforts. Cancer Discov; 8(2); 196–215. ©2017 AACR. See related commentary by Balko and Sosman, p. 143. See related article by Deng et al., p. 216. This article is highlighted in the In This Issue feature, p. 127
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We did not observe an effect of IgG4 antibody control (Extended Data Fig. 2b), consistent with previous reports 14,19 .”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Ex vivo profiling using murine-derived organotypic tumour spheroids (MDOTS) 14 derived from untreated mice bearing B16-ova tumours confirmed enhanced response to anti-PD-1 plus TBK1i (Fig. 1e).”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“and that disrupting TBK1 signaling has shown early promise enhancing response to ICB in murine tumour models 14,15 .”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944 · cited 1×
“Although reported sources of CCL19 and CXCL13 include stromal, immune, and tumor cells, a recent high-resolution study using single-cell RNA sequencing (RNA-seq) of melanoma specimens demonstrated CCL19 expression in cancer-associated fibroblasts (CAF) and CXCL13 with CD8+ exhausted T cells (46).”
BackgroundSelf-citationSpatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422 · cited 2×
“As PD-1 blockade promotes immune cell infiltration in vivo (13), we also performed singlesample gene set enrichment analysis (ssGSEA) using published immune signatures (37), which revealed enrichment of diverse immune cell populations in a subset of patients (group A) treated with ICB (Fig.”
Method
Cited by
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
“For MDOTS experiments, CT26GFP+cells (2x106) were subcutaneously injected into the right flank using a 27 g needle and tumors were harvested 14 days post transplantation.”
InfluentialSelf-citationOrganoid modeling of the tumor immune microenvironment
Neal, J. T., Li, X., Zhu, J., Giangarra, V., Grzeskowiak, C. L., Ju, J., Liu, I. H., Chiou, S.-H., Salahudeen, A. A., Smith, A. R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.11.021 · Cited by 1,556
“Alternatively, custom microfluidic devices with human tumor suspension-derived microspheroids containing immune cells exhibit response to immunotherapeutics, but without tumor-immune specificity (Deng et al., 2018; Jenkins et al., 2018).”
BackgroundMethodA Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,392
Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening
Kim, M., Mun, H., Sung, C. O., Cho, E. J., Jeon, H.-J., Chun, S.-M., Jung, D. J., Shin, T. H., Jeong, G. S., Kim, D. K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11867-6 · Cited by 812
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0915 · Cited by 770
Self-citation
Metadata
- Authors
- Jenkins, R. W., Aref, A. R., Lizotte, P. H., Ivanova, E., Stinson, S., Zhou, C. W., Bowden, M., Deng, J., Liu, H., Miao, D., He, M. X., Walker, W., Zhang, G., Tian, T., Cheng, C., Wei, Z., Palakurthi, S., Bittinger, M., Vitzthum, H., Kim, J. W., Merlino, A., Quinn, M., Venkataramani, C., Kaplan, J. A., Portell, A., Gokhale, P. C., Phillips, B., Smart, A., Rotem, A., Jones, R. E., Keogh, L., Anguiano, M., Stapleton, L., Jia, Z., Barzily-Rokni, M., Cañadas, I., Thai, T. C., Hammond, M. R., Vlahos, R., Wang, E. S., Zhang, H., Li, S., Hanna, G. J., Huang, W., Hoang, M. P., Piris, A., Eliane, J.-P., Stemmer-Rachamimov, A. O., Cameron, L., Su, M.-J., Shah, P., Izar, B., Thakuria, M., LeBoeuf, N. R., Rabinowits, G., Gunda, V., Parangi, S., Cleary, J. M., Miller, B. C., Kitajima, S., Thummalapalli, R., Miao, B., Barbie, T. U., Sivathanu, V., Wong, J., Richards, W. G., Bueno, R., Yoon, C. H., Miret, J., Herlyn, M., Garraway, L. A., Van Allen, E. M., Freeman, G. J., Kirschmeier, P. T., Lorch, J. H., Ott, P. A., Hodi, F. S., Flaherty, K. T., Kamm, R. D., Boland, G. M., Wong, K.-K., Dornan, D., Paweletz, C. P., & Barbie, D. A.
- Affiliations
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Gilead Sciences (United States) (US)
- Broad Institute (US)
- The Wistar Institute (US)
- New Jersey Institute of Technology (US)
- 11Center for Applied Medical Research, University of Navarra, Pamplona, Spain.
- Brigham and Women's Hospital (US)
- Massachusetts Institute of Technology (US)
- 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Corresponding author
- Dornan, David
- Barbie, David A.
- ORCID
- Jenkins, Russell W.
- Aref, Amir R.
- Lizotte, Patrick H.
- Ivanova, Elena
- Zhou, Chensheng W.
- Bowden, Michaela
- Deng, Jiehui
- Liu, Hongye
- Miao, Diana
- He, Meng Xiao
- Zhang, Gao
- Tian, Tian
- Cheng, Chaoran
- Wei, Zhi
- Palakurthi, Sangeetha
- Portell, Andrew
- Gokhale, Prafulla C.
- Smart, Alicia
- Rotem, Asaf
- Jones, Robert E.
- Keogh, Lauren
- Jia, Zhiheng
- Barzily-Rokni, Michal
- Cañadas, Israel
- Thai, Tran C.
- Wang, Eric S.
- Zhang, Hua
- Li, Shuai
- Hanna, Glenn J.
- Huang, Wei
- Hoang, Mai P.
- Piris, Adriano
- Stemmer-Rachamimov, Anat O.
- Cameron, Lisa
- Shah, Parin
- Izar, Benjamin
- Thakuria, Manisha
- LeBoeuf, Nicole R.
- Rabinowits, Guilherme
- Parangi, Sareh
- Cleary, James M.
- Miller, Brian C.
- Kitajima, Shunsuke
- Thummalapalli, Rohit
- Barbie, Thanh U.
- Wong, Joshua
- Richards, William G.
- Bueno, Raphael
- Yoon, Charles H.
- Miret, Juan
- Herlyn, Meenhard
- Garraway, Levi A.
- Freeman, Gordon J.
- Lorch, Jochen H.
- Ott, Patrick A.
- Hodi, F. Stephen
- Flaherty, Keith T.
- Kamm, Roger D.
- Boland, Genevieve M.
- Wong, Kwok-Kin
- Paweletz, Cloud Peter
- Barbie, David A.
- Venue
- Cancer Discovery
- Published
- 2018-02-01
- Volume
- 8
- Issue
- 2
- Pages
- 196-215
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC5809290
- OpenAlex
- W2766123339
- Cited by
- 594
- References
- 62
- Citations by year
- 2026: 67 · 2025: 76 · 2024: 91 · 2023: 73 · 2022: 76 · 2021: 73 · 2020: 72 · 2019: 37 · 2018: 28
- FWCI
- 16.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- HHS | NIH | National Cancer Institute (NCI) (NCI T32 CA009172-41, 1R01CA149738-01, NCI-R01 CA190394-01, P01CA120964, 5R01CA163896-04, 5R01CA140594-07, 5R01CA122794-10, 5R01CA166480-04)
- SU2C (SU2C-AACR-DT17-15)
- HHS | NIH | National Institute of General Medical Sciences (NIGMS) (NIGMS T32 GM008313)
- National Science Foundation (NSF) (NSF GRFP DGE1144152)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- anti-PD-1 therapy, immune checkpoint blockade, tumor microenvironment, immunotherapy resistance, cytokine production, precision immuno-oncology, combination therapy, microfluidic culture, patient-derived tumor models
- MeSH terms
- Antineoplastic Agents, Immunological, Animals, Flow Cytometry, Humans, Immunohistochemistry, Tumor Cells, Cultured, Immunophenotyping, Cytokines, Spheroids, Cellular, Cell Culture Techniques, Drug Resistance, Neoplasm, Cell Line, Tumor, Microfluidic Analytical Techniques, Mice, Time-Lapse Imaging, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. https://app.cochat.ai/papers/10.1158/2159-8290.cd-17-0833
- The paper
- Jenkins, R. W., Aref, A. R., Lizotte, P. H., Ivanova, E., Stinson, S., Zhou, C. W., Bowden, M., Deng, J., Liu, H., Miao, D., He, M. X., Walker, W., Zhang, G., Tian, T., Cheng, C., Wei, Z., Palakurthi, S., Bittinger, M., Vitzthum, H., . . . Barbie, D. A. (2018). Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-17-0833
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.